EMLA™

What Is EMLA® Cream? Ingredients and Eutectic Mechanism

The name EMLA® is short for Eutectic Mixture of Local Anaesthetics, and it describes exactly what the formulation is built to do. Two amide-type local anaesthetics, lidocaine 25 mg/g and prilocaine 25 mg/g, are combined in equal parts so that their mixture melts at a lower temperature than either agent does on its own. The drop in melting point lets both actives sit in a liquid oil phase inside an oil-in-water emulsion, allowing a comparatively modest total drug load to penetrate intact skin at a higher effective concentration than a single-agent cream of similar strength could manage.[1]

Once the emulsion reaches the nerve endings in the epidermis and dermis, both agents block the sodium channels that a nerve needs to fire, which is how the numbing effect is produced. AstraZeneca developed the original formulation, and Aspen Pharma handles distribution across a range of international markets. Because EMLA® sits inside the pharmaceutical framework rather than the cosmetic or medical-device one, sourcing it involves regulatory checks that do not apply to the aesthetic-brand numbing products.

EMLA® Products – How to Buy EMLA® Cream Online

• EMLA® Cream (tube-format): Comes in 5 g and 30 g tubes depending on market, and clinics can measure out the amount they need for the treatment area in front of them. That suits irregular sites, several small areas at once, or any scenario where a fixed dose would waste product. Most practitioners referring to EMLA® numbing cream or EMLA® lidocaine cream have this format in mind.
• EMLA® Patch: Delivers 25 mg of lidocaine and 25 mg of prilocaine under a built-in occlusive backing, so there is no separate dressing step, and the dose and contact area are fixed.[3] That fixed geometry rules it out for large or irregular treatment sites, but it suits a routine venipuncture where the target is small and defined. Departments running high blood-draw volumes prefer the patch for exactly that reason. Availability varies by market.

Clinical Indications and Aesthetic Uses

Approved indications differ by country and by presentation, but the coverage on the label is broadly consistent. EMLA® is licensed for skin anesthesia before venipuncture, IV cannulation, blood sampling, and needle insertion, and for use before a range of superficial skin procedures.

In aesthetic practice, common applications include:

• Pre-laser numbing, whether ablative or non-ablative
• Microneedling and pre-injection prep within mesotherapy protocols
• Electrolysis
• Minor skin surgery and other superficial dermatological procedures

A meta-analysis of eutectic lidocaine-prilocaine cream applied under occlusion before venipuncture and intravenous insertion found consistent reductions in perceived pain across pediatric and adult populations at standard needle gauges.[4] That trial volume is a large part of why EMLA® remains the reference point when the goal is a documented reduction in venipuncture pain rather than sedation.

Clinics evaluating where to buy EMLA® cream should still match the presentation to the intended procedure, since a patch that fits a venipuncture site will not cover a broad microneedling zone, and a 30 g cream tube may be more than a single-procedure practice needs on hand.

EMLA® Efficacy in Heavily Pigmented Skin

A controlled study assigned volunteers to three pigmentation groups and applied lidocaine/prilocaine cream to one arm and placebo to the other for 60, 90, or 120 minutes before venipuncture, with perceived pain scored on a visual analog scale afterward.[2]

At 60 minutes, the cream reduced perceived pain compared with placebo in every group, and the difference between the three pigmentation groups was not statistically significant. Extending the application to 90 or 120 minutes did not add relief that shorter application had missed. The reading that follows from that data is that the anesthetic efficacy of EMLA® is not systematically reduced in heavily pigmented skin at standard application times.

These findings suggest the following:

• Blanching and erythema are easier to see on lighter skin, so the absence of an obvious visual change is not itself evidence that the cream has not taken effect.
• Ordinary patient-to-patient variation in penetration exists regardless of pigmentation type. Where a specific patient is slow to numb, extending occlusion within the approved range is defensible; assuming pigmentation is the reason is not what the trial data supports.

How to Apply EMLA® Cream – Protocol and Timing

Apply EMLA® cream directly to intact skin in a thick, visible layer, then cover with an occlusive dressing to support consistent absorption. The required amount and application time depend on the patient’s age, treatment area, procedure, and desired depth of anesthesia. For minor procedures on intact adult skin, product information commonly recommends around 1.5 to 2 g per 10 cm², although indication-specific instructions should always take priority. Do not rub the cream in completely; remove both the dressing and any remaining product before cleaning and preparing the site for treatment.[1]

Onset under occlusion typically begins at 45 to 60 minutes, and the effect deepens between 60 and 120 minutes.[1] For routine needle work on intact skin, 60 minutes of contact is generally the minimum to plan around. Procedures aiming for deeper anesthesia, ablative laser being the common example, usually call for 90 to 120 minutes. Once the cream and dressing come off, anesthesia typically persists for a further one to two hours. Longer than necessary is not automatically better, since large areas, prolonged exposure, and application over broken skin all increase systemic absorption, and the label limits exist for that reason.[5]

Regulatory and OTC Classification

EMLA® is regulated as a licensed pharmaceutical rather than as a cosmetic or medical device, and its classification is not uniform between markets. In many European jurisdictions, small pack sizes are supplied over the counter as pharmacy (P) medicines for defined indications including venipuncture and minor skin procedures, while larger packs or different indications remain prescription-only. In other jurisdictions, the product is prescription-only across all pack sizes.

That variability is the reason OTC EMLA® cream availability should never be assumed. The medicines and medical devices framework that governs EMLA® supply also governs the paperwork clinics need to hold, and this is where the pharmaceutical route diverges most clearly from the cosmetic-sector aesthetic numbing products. Doctor Medica’s staff can share information on EMLA®’s regulatory position across markets and on the sourcing routes open to licensed practitioners.

EMLA® Compared With Aesthetic Brand Topical Anesthetics

vs FILLMED

FILLMED, the Filorga group’s professional line, includes meso-anesthesia preparations within its mesotherapy range: topical lidocaine-based products designed to numb skin ahead of injection protocols. These are professional aesthetic products rather than licensed pharmaceutical anesthetics. For a clinic running mesotherapy work, EMLA® applied under occlusion beforehand offers pharmaceutical-grade numbing supported by published venipuncture and skin-procedure evidence, while FILLMED’s meso-anesthesia range is built specifically for pre-injection skin preparation and may include additional actives directed at that job.

vs BCN

The mesotherapy portfolio from Institut BCN includes topical anesthetic preparations aimed at making injection sessions more comfortable. Like the other comparators here, these are aesthetic-sector products classified as cosmetics or medical devices, not licensed medicines. EMLA® stands apart in this group for its regulatory framework, approved indications for venipuncture and minor skin work, and the trial base supporting it.

vs MESOESTETIC

MESOESTETIC has developed professional treatment-preparation products and has also reported a topical anesthetic product in some markets. Check local regulations for exact active ingredients, registration, and authorized uses. EMLA® remains distinct because its lidocaine-prilocaine eutectic formula and pharmaceutical instructions are clearly defined.

vs MEDIDERMA

MEDIDERMA’s professional aesthetic range includes topical anesthetic preparations built around lidocaine, positioned for pre-procedure use in cosmetic practice. As with the other comparators in this section, its topical anesthetics carry a cosmetic or medical device classification rather than a pharmaceutical one. Clinical trials have documented the efficacy of EMLA® cream in reducing perceived procedural pain across multiple procedure types, which practitioners rely on when a treatment file needs to show trial evidence rather than product-brochure claims.

vs SESDERMA

SESDERMA‘s numbing option, a single-agent lidocaine cream, is used in aesthetic settings ahead of procedures where mild surface anesthesia is enough. It does not use the eutectic mixture that EMLA® is built around, and depending on product and market, it is registered as a CE-marked cosmetic or medical device rather than a pharmaceutical. Where the procedure calls for depth of numbing and a documented efficacy base, whether that is laser, venipuncture, or minor surgery, the pharmaceutical framing is the differentiator that matters.

Clinical Benefits of EMLA® for Practitioners

The dual-agent eutectic formulation gives deeper, more reliable numbing than the single-agent lidocaine creams the aesthetic brands sell, at a lower total drug load than either agent could reach on its own. The pharmaceutical regulatory status simplifies the audit and compliance side of clinical governance in a way cosmetic and medical device alternatives do not. And having both a cream and a patch on offer means the format can follow the procedure rather than the other way round.

Most practitioners rely on published clinical evidence in written protocols. The efficacy of EMLA® cream has been documented across venipuncture, minor surgical procedures, and superficial dermatology, and the pigmentation trial data addresses a specific practical question that comes up in mixed patient populations.[2][4] Where clinics buy EMLA® numbing cream to standardize a numbing protocol across procedure types, the ability to point to those trials in the file is part of the value of choosing a licensed pharmaceutical over a cosmetic-classified alternative.

Storage and Handling

Storage should follow the labeling on the specific pack, since limits vary between markets. Product information commonly specifies that EMLA® cream should not be stored above 25°C and should not be frozen.[1] There is no cold-chain requirement, which simplifies shipping and handling compared with temperature-sensitive injectables. Tubes should stay tightly closed between uses, and staff who handle EMLA® cream frequently should minimize unnecessary skin contact, since repeated cutaneous exposure can contribute to sensitization.

Before use, clinics should confirm the product name and strength, LOT number, expiration date, packaging integrity, and market-specific leaflet. Shipping arrangements should still preserve the pharmaceutical chain of custody even without cold-chain constraints, and the shipping paperwork clinics receive should match the pack delivered.

Pricing, Procurement, and How to Buy EMLA® Wholesale

EMLA® is priced as a pharmaceutical, not an aesthetic-catalog product, so the tube price is only part of what a clinic ends up paying. Tube size (5 g or 30 g), supplier, market, order volume, VAT, import duties, and any wholesale licensing rules in the destination country all factor in.

Cost per gram is a more useful comparison than pack price alone. A larger tube is only cheaper in practice if the clinic uses it before expiry, so it helps to match pack size to actual case volume and storage. Practitioners planning to buy EMLA® wholesale should also check whether their country requires a wholesale distributor license for the pack size they want, and confirm supplier paperwork before placing the order, not after.

To buy EMLA® online for a licensed practice, or to find out where to buy EMLA® cream in a specific market, Doctor Medica’s staff can share information on current formats, pricing, documentation, and availability.

Side Effects and Contraindications of EMLA® 

Common EMLA® reactions are localized and transient: pallor or blanching at the application site, erythema, mild edema, warmth, itching, tingling, and occasional brief burning as the cream takes effect.[1] Less frequently reported are hypersensitivity reactions, eye irritation from accidental exposure, petechiae, and purpura.

The more specific safety concern is methemoglobinemia, driven by prilocaine metabolism. Risk rises with excessive doses, prolonged application, large treatment areas, application to broken skin, use in preterm neonates, G6PD deficiency, and concurrent methemoglobin-inducing medicines. Suspected cases, signaled by grey or blue skin discoloration, dyspnoea, dizziness, fatigue, confusion, or an abnormal heart rate, need urgent assessment.

Contraindications include hypersensitivity to lidocaine, prilocaine, or other amide-type local anesthetics; hypersensitivity to any formulation ingredient; congenital or idiopathic methemoglobinemia; and use in preterm infants born before 37 weeks gestational age without specialist supervision.

EMLA® should not be applied on open wounds, infected or inflamed skin, or mucous membranes unless product labeling specifically permits that use for the indication in question, and it should not be used where the product could enter the middle ear or come into contact with the eyes.[1] Atopic dermatitis can increase both local reactions and systemic absorption, and a shorter exposure time may be appropriate for those patients.

How to Find Information for Professionals Looking to Buy EMLA®

EMLA®’s market-by-market classification as prescription-only or pharmacy-regulated is the starting point for any sourcing decision, and the checks a licensed practitioner should make before they order EMLA® online or arrange wholesale supply begin with confirming the local regulatory category. From there, distribution should go through authorized channels rather than informal ones, which matters in particular for a licensed medicine subject to shipping and storage standards.

Requirements for purchasing EMLA® online vary by jurisdiction, and licensed professionals are best served by confirming what their regional regulations permit before placing an order. For clinics evaluating wholesale routes, questions to answer before the first order include distributor credentials, LOT documentation, storage and handling during transit, and applicable regulatory paperwork for the destination market. A licensed practice looking to buy EMLA® online through verified channels should ask the same questions regardless of pack size.

At Doctor Medica, we work with licensed medical and aesthetic practitioners across a range of markets and can share information on EMLA® availability and the sourcing options available to verified clinics. Practitioners looking to buy EMLA® cream for their practice, or trying to identify a supplier for a specific market, can contact Doctor Medica’s staff for guidance.

Frequently Asked Questions

What is EMLA® cream?

EMLA® is a licensed topical anesthetic pairing lidocaine 2.5% with prilocaine 2.5% in a eutectic oil-in-water emulsion, developed by AstraZeneca and distributed by Aspen Pharma. The eutectic formulation allows it to reach a higher effective anesthetic concentration at the skin surface than a comparable single-agent EMLA® lidocaine cream alternative.

What are EMLA® cream ingredients?

The two active agents are lidocaine 25 mg/g and prilocaine 25 mg/g. Excipients typically include carbomer, macrogolglycerol hydroxystearate, sodium hydroxide, and purified water, though the specific excipient list can vary between market authorizations.

What are the main EMLA® cream uses?

Skin anesthesia before venipuncture, IV cannulation, blood sampling, needle insertion, laser sessions, microneedling, mesotherapy, electrolysis, and other superficial skin procedures.

How long does EMLA® take to work?

Under occlusion, onset generally begins at 45 to 60 minutes, with a stronger effect at 90 to 120 minutes depending on the indication and treatment site. Anesthesia typically persists for a further one to two hours after the cream is removed.

Does EMLA® work on heavily pigmented skin?

Yes. A controlled trial across three pigmentation groups found a significant reduction in venipuncture pain versus placebo at standard application times, with no significant difference in efficacy between the pigmentation groups.[2]

Is there an EMLA® patch?

Yes, in some markets. Each patch contains 25 mg of lidocaine and 25 mg of prilocaine under a built-in occlusive backing and is designed for a venipuncture-sized site.

Where can practitioners find information about buying EMLA®?

Doctor Medica’s staff can provide information on current formats, documentation, and market-specific availability for licensed practitioners.

For licensed medical professionals only. This content is for informational purposes only and does not constitute medical advice.

Citations and Resources

[1] European Medicines Agency. EMLA Cream: Summary of Product Characteristics and Package Leaflet (Article 30 Referral, Annex III). European Medicines Agency, www.ema.europa.eu/en/documents/referral/emla-cream-article-30-referral-annex-iii_en.pdf.

[2] Riendeau, L A et al. “Evaluation of the analgesic efficacy of EMLA cream in volunteers with differing skin pigmentation undergoing venipuncture.” Regional anesthesia and pain medicine vol. 24,2 (1999): 165-9. doi:10.1016/s1098-7339(99)90079-2

[3] Health Canada. Emla® (Lidocaine and Prilocaine Cream): Product Monograph. AstraZeneca Canada Inc., www.pdf.hres.ca/dpd_pm/00040608.PDF.

[4] Fetzer, Susan Jane. “Reducing venipuncture and intravenous insertion pain with eutectic mixture of local anesthetic: a meta-analysis.” Nursing research vol. 51,2 (2002): 119-24. doi:10.1097/00006199-200203000-00008

[5] U.S. Food and Drug Administration. EMLA (Lidocaine and Prilocaine) Cream: Prescribing Information. Revised Apr. 2018, U.S. Food and Drug Administration, www.accessdata.fda.gov/drugsatfda_docs/label/2018/019941s021lbl.pdf.

Written by Doctor Medica’s Editorial team

The content on this page has been written and fact-checked in accordance with our Editorial Policy. Clinical claims are sourced from peer-reviewed literature, regulatory documentation, and manufacturer specifications. Where citations are provided, it is always in accordance to our editorial standards.

Doctor Medica sources products exclusively through authorized distributors and established procurement channels. Products are verified as genuine, and supplied in the original packaging with their seal intact. Learn more about how we guarantee product authenticity, sourcing compliance, and traceable delivery to our clients.